Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results

Disc Medicine (NASDAQ:IRON) issued its quarterly earnings results on Thursday. The company reported ($1.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07, FiscalAI reports. The business had revenue of ($19.88) million for the quarter.

Disc Medicine Trading Up 1.5%

Shares of IRON stock traded up $1.02 on Thursday, hitting $67.91. 907,172 shares of the company’s stock traded hands, compared to its average volume of 937,199. The stock has a market capitalization of $2.56 billion, a price-to-earnings ratio of -12.69 and a beta of 0.88. The company’s fifty day simple moving average is $74.70 and its 200 day simple moving average is $75.34. Disc Medicine has a one year low of $30.82 and a one year high of $99.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45.

Insider Buying and Selling at Disc Medicine

In related news, COO Jonathan Yen-Wen Yu sold 3,231 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $203,100.66. Following the completion of the sale, the chief operating officer directly owned 54,324 shares in the company, valued at $3,414,806.64. This represents a 5.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Rahul Khara sold 2,853 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total value of $179,339.58. Following the transaction, the insider owned 52,173 shares in the company, valued at approximately $3,279,594.78. The trade was a 5.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 284,761 shares of company stock valued at $24,913,484. 3.64% of the stock is currently owned by insiders.

Institutional Trading of Disc Medicine

A number of institutional investors have recently made changes to their positions in the stock. Police & Firemen s Retirement System of New Jersey increased its stake in shares of Disc Medicine by 3.3% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after buying an additional 215 shares during the period. Kennedy Capital Management LLC grew its holdings in Disc Medicine by 3.3% in the 4th quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock worth $740,000 after acquiring an additional 296 shares during the last quarter. Alliancebernstein L.P. grew its holdings in Disc Medicine by 1.7% in the 3rd quarter. Alliancebernstein L.P. now owns 24,540 shares of the company’s stock worth $1,622,000 after acquiring an additional 400 shares during the last quarter. Swiss National Bank increased its position in shares of Disc Medicine by 1.6% in the third quarter. Swiss National Bank now owns 43,600 shares of the company’s stock valued at $2,881,000 after acquiring an additional 700 shares during the period. Finally, Virtus Investment Advisers LLC raised its stake in shares of Disc Medicine by 34.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 2,897 shares of the company’s stock valued at $230,000 after acquiring an additional 739 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on IRON shares. TD Cowen reiterated a “buy” rating on shares of Disc Medicine in a research report on Friday, December 19th. Wedbush dropped their price objective on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a report on Tuesday, February 17th. Stifel Nicolaus cut their target price on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Truist Financial increased their target price on Disc Medicine from $86.00 to $114.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Cantor Fitzgerald lowered their price target on Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Disc Medicine currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.82.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.